On June 17th, Gelun Hui reported that Sichuan Kelun Pharmaceutical (002422.SZ) announced that its subsidiary Sichuan Kelun Botai Biomedical Pharmaceutical Co., Ltd. (hereinafter referred to as "Kelun Botai") has received a clinical trial notice for the innovative drug injection SKB518 developed by the company's controlling subsidiary. The notice was approved by the National Medical Products Administration (NMPA) Drug Evaluation Center.
SKB518 for injection is an innovative antibody conjugate drug with independent intellectual property rights developed by Kelun Botai using the "OptiDCTM" platform technology based on the biological characteristics of the target. It has shown good effectiveness and safety window in preclinical stage and is intended for the treatment of advanced solid tumors.
Kelun Botai will organize clinical trials of SKB518 for injection in accordance with the clinical trial notice issued by National Medical Products Administration.